Nautilus Biotechnology Inc (NAUT)
2.65
+0.08
(+3.11%)
USD |
NASDAQ |
Nov 05, 16:00
2.65
0.00 (0.00%)
After-Hours: 19:13
Nautilus Biotechnology Enterprise Value: 182.09M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 182.09M |
| November 01, 2024 | 187.11M |
| October 31, 2024 | 185.86M |
| October 30, 2024 | 192.14M |
| October 29, 2024 | 207.20M |
| October 28, 2024 | 212.23M |
| October 25, 2024 | 197.16M |
| October 24, 2024 | 200.93M |
| October 23, 2024 | 204.68M |
| October 22, 2024 | 208.45M |
| October 21, 2024 | 207.19M |
| October 18, 2024 | 229.79M |
| October 17, 2024 | 219.75M |
| October 16, 2024 | 231.05M |
| October 15, 2024 | 215.98M |
| October 14, 2024 | 213.47M |
| October 11, 2024 | 218.49M |
| October 10, 2024 | 199.66M |
| October 09, 2024 | 209.70M |
| October 08, 2024 | 197.15M |
| October 07, 2024 | 193.38M |
| October 04, 2024 | 199.66M |
| October 03, 2024 | 189.61M |
| October 02, 2024 | 202.17M |
| October 01, 2024 | 198.40M |
| Date | Value |
|---|---|
| September 30, 2024 | 217.24M |
| September 27, 2024 | 197.50M |
| September 26, 2024 | 189.98M |
| September 25, 2024 | 186.22M |
| September 24, 2024 | 211.30M |
| September 23, 2024 | 181.83M |
| September 20, 2024 | 218.82M |
| September 19, 2024 | 208.79M |
| September 18, 2024 | 192.49M |
| September 17, 2024 | 196.88M |
| September 16, 2024 | 203.77M |
| September 13, 2024 | 196.25M |
| September 12, 2024 | 174.93M |
| September 11, 2024 | 177.44M |
| September 10, 2024 | 186.22M |
| September 09, 2024 | 166.15M |
| September 06, 2024 | 152.36M |
| September 05, 2024 | 154.86M |
| September 04, 2024 | 143.58M |
| September 03, 2024 | 151.10M |
| August 30, 2024 | 158.63M |
| August 29, 2024 | 156.12M |
| August 28, 2024 | 161.13M |
| August 27, 2024 | 163.64M |
| August 26, 2024 | 163.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-64.65M
Minimum
Dec 16 2022
1.288B
Maximum
Jun 10 2021
202.90M
Average
167.29M
Median
Apr 20 2023
Enterprise Value Benchmarks
| Incyte Corp | 12.82B |
| Merck & Co Inc | 284.72B |
| Neogen Corp | 3.896B |
| Pfizer Inc | 219.16B |
| Repligen Corp | 7.600B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.45M |
| Total Expenses (Quarterly) | 19.10M |
| EPS Diluted (Quarterly) | -0.13 |
| Earnings Yield | -21.13% |